BusinessMelinta Therapeutics to Highlight Commitment to Antibiotics and Product Portfolio at MAD-ID 2018 Annual MeetingBy Nasdaq OMXMay 8, 2018, 12:01 PM UTC
BusinessMelinta Therapeutics Receives Up to $6.2 Million from CARB-X to Advance Clinical Development of a Novel Antimicrobial to Combat Antibiotic-Resistant BacteriaBy Nasdaq OMXMay 7, 2018, 11:00 AM UTC
BusinessAccelerate Diagnostics to Review First Quarter 2018 Results on May 9thBy Nasdaq OMXApr 30, 2018, 2:42 PM UTC
BusinessAccelerate Diagnostics announces sizeable release of new data at ECCMID 2018By Nasdaq OMXApr 21, 2018, 7:38 AM UTC
BusinessMelinta Therapeutics Reports Fourth Quarter and Full Year 2017 Financial ResultsBy Nasdaq OMXMar 13, 2018, 11:01 AM UTC
BusinessMelinta Therapeutics Partner, Menarini Group, Submits Marketing Authorization Application for Delafloxacin in EuropeBy Nasdaq OMXMar 8, 2018, 12:01 PM UTC
BusinessMelinta Therapeutics Publishes Complete Results from Phase 3 TANGO I Study of VABOMERE™ (meropenem and vaborbactam) in Patients with cUTIBy Nasdaq OMXFeb 27, 2018, 9:05 PM UTC
BusinessAccelerate Diagnostics reports Q4 and Full-Year Financial Results for 2017By Nasdaq OMXFeb 15, 2018, 9:06 PM UTC
